RxDoctor Payments Data

Julie Tackett, NP

Nurse Practitioner · Rural Hall, NCNPI 1689924391

Payments from drug & device makers

$302in general payments, 2019–2025

Across 12 payments — averaging $25.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$109
  • Abbott$50
  • Boehringer Ingelheim$30
  • Pfizer$28
  • Exact Sciences$22
  • AbbVie$18
  • plus $45 from 3 others

What the payments were for

  • Speaking & faculty fees$155%
  • Food & beverage$28795%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC2$109
Abbott2$50
Boehringer Ingelheim2$30
Pfizer1$28
Exact Sciences1$22
AbbVie1$18
Novo Nordisk1$16
Mckesson Medical-surgical, Inc.1$15
AstraZeneca1$15

How this compares

$302 in reported general payments places this provider in the 60th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$7,370
Medicare patients
66
Services billed
111

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban40$20,535
XareltoRivaroxaban16$4,581
MyrbetriqMirabegron15$3,463
SymbicortBudesonide/Formoterol Fumarate12$2,917
Doxycycline Hyclate20$925
Methocarbamol12$432
Omeprazole18$414
Famotidine18$340
Escitalopram Oxalate19$319
Duloxetine Hcl13$311
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav13$263
Ondansetron Hcl12$229
Pregabalin13$220
Gabapentin17$214
Atorvastatin Calcium19$211

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$28$20,53540 claims
AstraZenecaSymbicort$15$2,91712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Rural Hall

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →